论文部分内容阅读
目的探讨阿托伐他汀对原发性高血压(EH)患者循环血单个核细胞(PBMC)分泌炎症细胞因子——肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、白细胞介素1β(IL-1β)的影响。方法40例血脂正常的EH男性患者随机分成阿托伐他汀治疗组(阿托伐他汀10 mg.d-1,qd,20例)及20例常规治疗组治疗3个月。采用密度梯度离心法分离PBMC,检测治疗前后PBMC分泌TNF-α、IL-6、IL-1β水平,20名年龄与性别相匹配的健康者作为正常对照。结果EH患者PBMC分泌TNF-α、IL-6、IL-1β水平明显高于正常对照组(P<0.01);治疗后PBMC分泌TNF-α、IL-6、IL-1β水平,阿托伐他汀组明显低于治疗前(P<0.01、P<0.05),常规治疗组则无显著差异(P>0.05)。两组治疗前后血压有显著差异(P<0.01),但组间无显著差异(P>0.05)。结论EH患者PBMC处于激活状态,存在炎症反应。阿托伐他汀可抑制PBMC分泌炎症细胞因子,可能有利于改善并延缓高血压的进程。
Objective To investigate the effects of atorvastatin on the secretion of inflammatory cytokines necrosis factor α (TNF-α), interleukin-6 (IL-6), and interleukin-6 (IL-6) in circulating blood mononuclear cells (PBMCs) from patients with essential hypertension Effect of Interleukin-1β (IL-1β). Methods Forty cases of EH male with normal blood lipids were randomly divided into atorvastatin group (atorvastatin 10 mg.d-1, qd, 20 cases) and 20 cases of conventional treatment group for 3 months. PBMCs were isolated by density gradient centrifugation. The levels of TNF-α, IL-6 and IL-1β secreted by PBMCs were measured before and after treatment. Twenty healthy and age-matched healthy individuals were selected as normal controls. Results The levels of TNF-α, IL-6 and IL-1β secreted by PBMC in EH patients were significantly higher than those in normal controls (P <0.01). The levels of TNF-α, IL-6 and IL- Group was significantly lower than before treatment (P <0.01, P <0.05), conventional treatment group was no significant difference (P> 0.05). Before and after treatment, blood pressure was significantly different (P <0.01), but there was no significant difference between the two groups (P> 0.05). Conclusion EH patients with activated PBMC, there is inflammation. Atorvastatin can inhibit PBMC secretion of inflammatory cytokines, which may be beneficial to improve and delay the progression of hypertension.